Supplemental Table 1. Hematotoxicity, hepatotoxicity and nephrotoxicity after PRRT according to CTCAE v.5.0

		Baseline	1st cycle		2nd cycle		3rd cycle	
			1 week	4 weeks	1 week	4 weeks	1 week	4 weeks
Group A	WBC	0/12	0/12	0/12	0/12	0/12	0/9	0/9
	PLT	0/12	0/12	0/12	0/12	0/12	0/9	0/9
	Hb	0/12	0/12	0/12	0/12	0/12	0/9	0/9
	ALT	**1/11**	0/12	0/12	0/12	0/12	0/9	0/9
	AST	0/12	**1/11**	0/12	0/12	0/12	0/9	0/9
	ALP	0/12	0/12	0/12	0/12	0/12	0/9	0/9
	Cr	0/12	0/12	0/12	0/12	0/12	0/9	0/9
Group B	WBC	0/6	0/6	0/6	0/5	0/5	0/5	0/5
	PLT	0/6	0/6	0/6	**1/4**	**1/4**	0/5	0/5
	Hb	0/6	0/6	0/6	0/5	0/5	0/5	0/5
	ALT	0/6	0/6	0/6	0/5	0/5	0/5	0/5
	AST	0/6	0/6	0/6	0/5	0/5	0/5	0/5
	ALP	1/5	0/6	0/6	0/5	0/5	0/5	0/5
	Cr	0/6	0/6	0/6	0/5	0/5	0/5	0/5
Group C	WBC	0/14	0/14	0/14	0/13	0/13	0/8	0/8
	PLT	0/14	0/14	**2/12**	**1/12**	**1/12**	0/8	0/8
	Hb	**1/13**	0/14	**1/13**	0/13	0/13	0/8	0/8
	ALT	0/14	0/14	0/14	0/13	0/13	0/8	0/8
	AST	0/14	0/14	**1/13**	0/13	0/13	0/8	0/8
	ALP	0/14	0/14	0/14	0/13	0/13	0/8	0/8
	Cr	0/14	0/14	0/14	0/13	0/13	0/8	0/8

The ratios: (cases with CTC-3) / (cases with CTC-0, CTC-1, and CTC-2)

WBC: white blood cell; Hb: hemoglobin; PLT: platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Cr: creatine; ALP: alkaline phosphatase

Supplemental Table 2. Changes of hematological parameters, liver and renal function between baseline and 4 weeks after PRRT in groups A-C

Hematological parameters									
Group	ΔWBC%			ΔHb%			ΔPLT%		
	1st	2nd	3rd	1st	2nd	3rd	1st	2nd	3rd
Group A	-4.7±12.7	-10.9±16.7	-5.7±29.2	-0.1±3.7	1.8±9.2	7.1±12.6	-13.9±9.5	-16.6±19.3	-23.3±18.5
Group B	-3.4±42.1	-21.7±21.9	-35.3±25.4	2.8±8.5	5.3±10.8	1.1±11.1	-0.1±23.0	-8.4±40.5	-3.3±42.7
Group C	-12.2±29.8	-22.3±39.7	-11.1±58.0	-9.6±9.5	-14.1±7.8	-17.2±14.4	-26.3±27.0	-29.4±33.7	-40.9±25.5
P value	NS	NS	NS	NS	<0.001 (<0.001^{A,C}, 0.001^{B,C})	0.015 (0.004^{A,C}, 0.011^{B,C})	NS	NS	NS
Liver and renal function									
Group	ΔALT%			ΔAST%			ΔCr%		
	1st	2nd	3rd	1st	2nd	3rd	1st	2nd	3rd
Group A	10.3±59.1	62.8±215.8	1.2±49.7	9.0±43.8	19.5±63.5	-5.0±29.2	13.8±21.0	11.5±18.6	10.5±22.9
Group B	-22.4±25.1	-32.4±21.1	-34.5±20.4	-24.9±27.5	-30.0±25.7	-34.2±30.4	-6.6±16.7	-10.2±16.6	-11.5±15.6
Group C	53.0±102.2	22.9±98.3	17.6±26.3	53.0±102.2	22.9±98.3	20.0±26.9	-6.4±19.0	-6.3±11.0	-4.1±18.4
P value	NS	NS	NS	NS	NS	NS	0.040 (0.035^{A,B}, 0.010^{A,C})	0.033 (0.016^{A,B}, 0.011^{A,C})	NS

NS: not significant; WBC: white blood cell; Hb: hemoglobin; PLT: platelet; ALT: alanine aminotransferase; AST: aspartate aminotransferase; Cr: creatine

Supplemental Table 3. Response evaluation by molecular imaging (^{68}Ga-DOTATATE PET/CT) referring to EORTC and modified PERCIST criteria

Efficacy	Group A				Group B				Group C			
	1st cycle (n= 12)	2nd cycle (n= 12)	3rd cycle (n= 9)	Overall	1st cycle (n= 6)	2nd cycle (n= 5)	3rd cycle (n= 5)	Overall	1st cycle (n= 14)	2nd cycle (n= 13)	3rd cycle (n= 8)	Overall
CR (%)	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0
PR (%)	50.0/16.7	41.7/25.0	44.4/22.2	50.0/33.3	50.0/33.3	60.0/60.0	60.0/40.0	50.0/33.3	50.0/14.3	30.8/30.8	37.5/37.5	42.9/35.7
SD (%)	33.3/66.7	33.3/50.0	22.2/44.4	16.7/33.3	50.0/66.7	40.0/40.0	40.0/60.0	33.3/66.7	42.9/71.4	38.5/38.5	25.0/37.5	28.6/42.9
PD (%)	16.7/16.7	25.0/25.0	33.3/33.3	33.3/33.3	0.0/0.0	0.0/0.0	0.0/0.0	16.7/0.0	7.1/14.3	23.1/23.1	25.0/12.5	28.6/21.4
NA (%)	0.0/0.0	0.0/0.0	0.0/0.0	-	0.0/0.0	0.0/0.0	0.0/0.0	-	0.0/0.0	7.7/7.7	12.5/12.5	-
DRR (%)	50.0/16.7	41.7/25.0	44.4/22.2	50.0/33.3	50.0/33.3	60.0/60.0	60.0/40.0	50.0/33.3	50.0/14.3	30.8/30.8	37.5/37.5	42.9/35.7
DCR (%)	83.3/83.3	75.0/75.0	66.7/66.7	66.7/66.7	100/100	100/100	100/100	83.3/100	92.9/85.7	69.3/69.3	62.5/75.0	71.5/78.6

The ratios: (rate with EORTC criteria) / (rate with modified PERCIST criteria)

NA: not available; DRR: disease response rate (CR+PR); DCR: disease control rate (CR+PR+SD)

Supplemental Table 4. Comparison of ΔSUVmax% among groups A-C in all patients when selecting comparable baseline SUVmax ranging from 15 to 40

Group	1st cycle	2nd cycle	3rd cycle
Group A	2.1±40.8	-9.3±41.1	-6.9±42.3
Group B	-38.7±10.0	-38.4±37.8	-49.2±30.9
Group C	-14.7±20.0	-21.2±23.2	-11.9±37.9
P value	0.001 ($0.001^{A,B}$,$0.006^{B,C}$)	0.135	0.044 ($0.019^{B,C}$)

Supplemental Table 5. Comparison of ΔSUVmax% among groups A-C in patients who received 3 cycles of PRRT when selecting comparable baseline SUVmax ranging from 15 to 40

Group	1st cycle	2nd cycle	3rd cycle
Group A	-8.2±32.1	-15.0±37.8	-3.7±47.7
Group B	-38.7±10.0	-38.4±37.8	-49.2±30.9
Group C	-15.8±26.5	-6.9±17.1	-11.9±37.9
P value	0.025 ($0.039^{A,B}$)	0.113	0.039 ($0.016^{A,B}$)

Supplemental Table 6. Comparison of tumor SUVmax between baseline and post-therapy among groups A-C in patients who received 3 cycles of PRRT

Group	Baseline SUVmax	Post-Therapy SUVmax					
		1st cycle	*P*	2nd cycle	*P*	3rd cycle	*P*
Group A	28.4±27.7	28.3±36.5	0.966	26.3±34.4	0.450	29.9±40.4	0.712
Group B	48.0±53.7	34.7±39.9	0.002	34.3±41.5	0.003	33.6±42.2	0.006
Group C	32.5±24.4	20.5±7.7	0.019	20.4±6.8	0.035	20.4±8.9	0.036